503A compounding pharmacies are built to create patient-specific medications with physician oversight. But increasingly, the FDA and state boards are applying manufacturing-level restrictions designed for mass-market drug production — even when no commercial alternative exists.
This is regulatory overreach, not public safety.
Who’s Being Harmed
Thousands of everyday prescriptions for patients with chronic conditions
Provider authority to prescribe customized therapies
Pharmacy access in underserved communities
Affordable alternatives when branded meds are cost-prohibitive
